K

Kidswell Bio Corporation
TSE:4584

Watchlist Manager
Kidswell Bio Corporation
TSE:4584
Watchlist
Price: 225 JPY 4.65% Market Closed
Market Cap: 11.2B JPY

Kidswell Bio Corporation
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Kidswell Bio Corporation
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
K
Kidswell Bio Corporation
TSE:4584
EPS (Diluted)
ÂĄ5
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
EPS (Diluted)
-ÂĄ13
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-1%
PeptiDream Inc
TSE:4587
EPS (Diluted)
-ÂĄ45
CAGR 3-Years
-85%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
EPS (Diluted)
-ÂĄ53
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Oncolys Biopharma Inc
TSE:4588
EPS (Diluted)
-ÂĄ81
CAGR 3-Years
2%
CAGR 5-Years
9%
CAGR 10-Years
2%
C
Cuorips Inc
TSE:4894
EPS (Diluted)
-ÂĄ80
CAGR 3-Years
-17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Kidswell Bio Corporation
Glance View

Market Cap
11.2B JPY
Industry
Biotechnology

Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 39 full-time employees. The company went IPO on 2012-11-30. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.

Kidswell Bio Corporation Intrinsic Value
HIDDEN
Show

See Also

What is Kidswell Bio Corporation's EPS (Diluted)?
EPS (Diluted)
5.8 JPY

Based on the financial report for Sep 30, 2025, Kidswell Bio Corporation's EPS (Diluted) amounts to 5.8 JPY.

Back to Top